Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Abstract Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as tissue-agnostic indication. Since 2017, the Food and Drug Administration (FDA) has approved t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-09-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-021-00328-3 |